Chief Medical Officer (GR)
Presenting a unique opportunity for a Chief Medical Officer with an emerging, specialty pharmaceutical company with a track record of success and three late stage products in the pipeline.
The Chief Medical Officer (CMO) provides executive leadership as well as hands-on management of the company’s clinical development programs. This candidate will bring strong clinical leadership, knowledge of drug development and clinical development processes in the pain therapeutic area. The CMO possesses a mission-oriented focus and will be successful in managing the company’s drug programs with third-party providers, regulatory bodies and clinicians.
The company is a specialty, life sciences company with a focus on products born out of novel and innovative drug delivery technologies that improve the clinical outcome in rare and orphan disease treatments. Their lead commercial opportunity, a novel treatment for post herpetic neuralgia, is entering Ph III clinical testing in 2018. An additional product in the rare-disease space will be filed shortly this year followed by another target entering phase III trials. A fourth target is advancing out of preclinical testing in 2H 2018. Located in the highly accessible New Jersey pharma corridor, the company is led by two entrepreneurial pharma veterans with a proven track record of founding, growing and successfully exiting companies with exceptional value. The company has access to significant funding sources, a high growth trajectory pipeline, and mid-term plans for an IPO.
The company possesses an entrepreneurial, collaborative culture where exceptional talent is sought and rewarded. The candidate they are seeking is a networked expert in their field, is a hands-on manager, and will flourish in an emerging growth organization. The company offers a competitive compensation package and a highly attractive equity opportunity.